Lotus Health Group (600186) Fundamentals 2026 — P/E 43.8x, Revenue Analysis | SniperIQ
Lotus Health Group (600186) is a CN-listed Consumer Defensive company in Packaged Foods with a market capitalization of ¥15.3B, trading at ¥8.56 on the SHH. This SniperIQ fundamentals page covers Lotus Health Group's valuation (P/E 43.8x, P/B 7.4x), profitability (net margin 9.6%), revenue (¥3.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Lotus Health Group's market cap?
Lotus Health Group (600186) has a market capitalization of approximately ¥15.3B, trading at ¥8.56 on the SHH. Market cap moves with the live share price.
What is Lotus Health Group's P/E ratio?
Lotus Health Group's trailing twelve-month P/E ratio is 43.8x, with a price-to-book (P/B) of 7.4x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Lotus Health Group?
Lotus Health Group runs a net profit margin of 9.6%, a gross margin of 27.8%, and an operating margin of 11.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lotus Health Group generate?
Lotus Health Group reported revenue of ¥3.5B for fiscal year 2025, with net income of ¥309M and earnings per share (EPS) of 0.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Lotus Health Group pay a dividend?
Lotus Health Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Lotus Health Group financially healthy?
Lotus Health Group carries a debt-to-equity ratio of 0.44x and a current ratio of 1.90x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Lotus Health Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lotus Health Group (600186) the key facts are: market cap ¥15.3B, P/E 43.8x, revenue ¥3.5B, 52-week range 5.26-15.93. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Lotus Health Group's full fundamentals live
Get Lotus Health Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.